TScan Therapeutics (TCRX) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Company overview and platform

• Founded in 2018, focused on next-generation TCR-T therapies for oncology and autoimmune diseases.

• Proprietary discovery platform enables identification of new TCR targets and high-affinity TCRs.

• Eight agents in clinical development: two for hematologic malignancies, six for solid tumors.

• Uses transposon-based GMP manufacturing for lower costs and faster development.

• Platform also applied to autoimmune disease targets, with a partnership in Crohn's disease.

Hematologic malignancies program

• Addresses unmet need in myeloid cancers post-allogeneic transplant, aiming to prevent relapse.

• Utilizes donor T cells engineered to target patient-specific antigens, sparing healthy donor-derived cells.

• Phase I trial shows all eight treated patients remain relapse-free with no detectable cancer, median follow-up over ten months.

• No safety concerns observed; dose level three likely to be recommended for phase two.

• Current addressable market is ~3,000 US patients annually, with potential to double by expanding HLA coverage.

Solid tumor program and ImmunoBank

• Solid tumors present heterogeneity; strategy is multiplex TCR therapy tailored to each patient's tumor targets and HLA type.

• ImmunoBank contains TCRs for multiple targets and HLAs, enabling customized combinations.

• Engineered T cells include both cytotoxic and helper T cells, and are resistant to TGF-beta immunosuppression.

• Six TCRs currently in the clinic, with plans to add more, increasing patient eligibility for multiplex therapy.

• FDA agreed to allow multiplex therapy in phase one after individual TCR safety is established.